Understanding retinoblastoma post-translational regulation for the design of targeted cancer therapies
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Janostiak, Radoslav
- dc.contributor.author Torres-Sanchez, Ariadna
- dc.contributor.author Posas Garriga, Francesc
- dc.contributor.author Nadal Clanchet, Eulàlia de
- dc.date.accessioned 2022-04-21T05:55:38Z
- dc.date.available 2022-04-21T05:55:38Z
- dc.date.issued 2022
- dc.description.abstract The retinoblastoma protein (Rb1) is a prototypical tumor suppressor protein whose role was described more than 40 years ago. Together with p107 (also known as RBL1) and p130 (also known as RBL2), the Rb1 belongs to a family of structurally and functionally similar proteins that inhibits cell cycle progression. Given the central role of Rb1 in regulating proliferation, its expression or function is altered in most types of cancer. One of the mechanisms underlying Rb-mediated cell cycle inhibition is the binding and repression of E2F transcription factors, and these processes are dependent on Rb1 phosphorylation status. However, recent work shows that Rb1 is a convergent point of many pathways and thus the regulation of its function through post-translational modifications is more complex than initially expected. Moreover, depending on the context, downstream signaling can be both E2F-dependent and -independent. This review seeks to summarize the most recent research on Rb1 function and regulation and discuss potential avenues for the design of novel cancer therapies.
- dc.description.sponsorship This project received funding from the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie PROBIST grant agreement No. 754510 (postdoctoral fellowship to R.J.) and from BIST Living Allowance Fellowship to A.T.-S. This work was supported by grants from the Spanish Ministry of Economy and Competitiveness [BFU2017-85152-P and FEDER to E.d.N. and PGC2018-094136-B-I00 and FEDER to F.P.], the AECC Foundation [PROYE18010POSA to F.P.] and the Government of Catalonia [2017 SGR 799 to E.d.N. and F.P.]. E.d.N. and F.P. are recipients of ICREA Acadèmia awards (Government of Catalonia). We gratefully acknowledge institutional funding from the Ministry of Science, Innovation and Universities through the Centres of Excellence Severo Ochoa Award, and from the CERCA Programme of the Government of Catalonia and the Unidad de Excelencia María de Maeztu, funded by the AEI (CEX2018-000792-M).
- dc.format.mimetype application/pdf
- dc.identifier.citation Janostiak R, Torres-Sanchez A, Posas F, de Nadal E. Understanding retinoblastoma post-translational regulation for the design of targeted cancer therapies. Cancers (Basel). 2022 Feb 28;14(5):1265. DOI: 10.3390/cancers14051265
- dc.identifier.doi http://dx.doi.org/10.3390/cancers14051265
- dc.identifier.issn 2072-6694
- dc.identifier.uri http://hdl.handle.net/10230/52866
- dc.language.iso eng
- dc.publisher MDPI
- dc.relation.ispartof Cancers (Basel). 2022 Feb 28;14(5):1265
- dc.relation.projectID info:eu-repo/grantAgreement/EC/H2020/754510
- dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/BFU2017-85152-P
- dc.relation.projectID info:eu-repo/grantAgreement/ES/2PE/PGC2018-094136-B-I00
- dc.rights © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by/4.0/
- dc.subject.keyword Cancer therapies
- dc.subject.keyword Cell cycle
- dc.subject.keyword Retinoblastoma
- dc.title Understanding retinoblastoma post-translational regulation for the design of targeted cancer therapies
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion